Cidara Therapeutics, Inc. (NASDAQ:CDTX) COO Sells $36,541.44 in Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX) COO Shane Ward sold 1,664 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $36,541.44. Following the sale, the chief operating officer now owns 14,674 shares of the company’s stock, valued at $322,241.04. This trade represents a 10.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Cidara Therapeutics Price Performance

Shares of NASDAQ:CDTX opened at $22.05 on Friday. The business’s 50 day simple moving average is $22.08 and its 200-day simple moving average is $17.80. The firm has a market capitalization of $155.39 million, a price-to-earnings ratio of -0.86 and a beta of 0.88. Cidara Therapeutics, Inc. has a 12 month low of $10.00 and a 12 month high of $28.42.

Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%. On average, equities analysts anticipate that Cidara Therapeutics, Inc. will post -8.74 earnings per share for the current year.

Institutional Investors Weigh In On Cidara Therapeutics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of Cidara Therapeutics by 22.7% during the 3rd quarter. Geode Capital Management LLC now owns 52,898 shares of the biotechnology company’s stock worth $569,000 after acquiring an additional 9,771 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Cidara Therapeutics in the 3rd quarter valued at approximately $7,558,000. Checkpoint Capital L.P. lifted its stake in Cidara Therapeutics by 25.5% in the 3rd quarter. Checkpoint Capital L.P. now owns 182,426 shares of the biotechnology company’s stock valued at $1,961,000 after buying an additional 37,009 shares in the last quarter. Stempoint Capital LP purchased a new stake in Cidara Therapeutics in the 4th quarter valued at approximately $1,281,000. Finally, Schonfeld Strategic Advisors LLC lifted its stake in Cidara Therapeutics by 154.1% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 49,557 shares of the biotechnology company’s stock valued at $1,332,000 after buying an additional 30,057 shares in the last quarter. Hedge funds and other institutional investors own 35.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. WBB Securities increased their target price on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the stock a “strong-buy” rating in a research note on Thursday, December 5th. Citigroup assumed coverage on shares of Cidara Therapeutics in a research note on Wednesday. They set an “outperform” rating for the company. HC Wainwright increased their target price on shares of Cidara Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Cidara Therapeutics in a report on Friday, March 7th. Finally, Citizens Jmp began coverage on Cidara Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $46.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $39.14.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.